Latest Articles
A Lipid Metabolism and Lysosome-based Risk Signature for Prognosis and Immune Response Prediction in Uterine Corpus Endometrial Carcinoma - Frontiers
A Lipid Metabolism and Lysosome-based Risk Signature for Prognosis and Immune Response Prediction in Uterine Corpus Endometrial Carcinoma Frontiers
Published: Aug. 18, 2025, 5:24 p.m.
RNA-Seq transcriptome profiling reveals distinct immune response landscapes to identifying inflammation-related diagnostic markers in latent endometrial tuberculosis - Nature
RNA-Seq transcriptome profiling reveals distinct immune response landscapes to identifying inflammation-related diagnostic markers in latent endometrial tuberculosis Nature
Published: April 10, 2025, 7:28 p.m.
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer | Scientific Reports - Nature.com
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer | Scientific Reports Nature.com
Published: Dec. 28, 2024, 2:37 a.m.
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer - Nature.com
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer Nature.com
Published: Dec. 28, 2024, 2:37 a.m.
Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer - The Manila Times
Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer The Manila Times
Published: Nov. 5, 2024, 2:11 p.m.
Link copied to clipboard!